MedPlus Health Q3 FY26 Revenue Jumps 15.7%, Profit Soars 26% on Expansion

OTHER
Whalesbook Logo
AuthorVihaan Mehta|Published at:
MedPlus Health Q3 FY26 Revenue Jumps 15.7%, Profit Soars 26% on Expansion
Overview

MedPlus Health Services reported a robust Q3 FY2026 with revenue climbing 15.7% YoY to ₹18,061 million and PAT increasing 26.0% to ₹577.9 million. The pharmacy chain added 182 net stores, pushing its network to 5,112, with a focus on non-tier-one cities. Gross margins improved 110 bps YoY to 26.2%, and Operating EBITDA grew 21.1% YoY.

📉 The Financial Deep Dive

MedPlus Health Services has posted strong financial results for Q3 FY2026, signaling sustained growth and strategic expansion. The company's revenue for the quarter reached ₹18,061 million, marking a significant 15.7% year-on-year (YoY) increase and a healthy 7.5% quarter-on-quarter (QoQ) growth.

The Numbers:

  • Revenue: ₹18,061 million (+15.7% YoY, +7.5% QoQ)
  • Gross Margin: ₹4,724 million (26.2% of revenue, +110 bps YoY)
  • Operating EBITDA: ₹968 million (+21.1% YoY)
  • Pharmacy Operating EBITDA Margin: 5.2% (+10 bps QoQ)
  • Profit After Tax (PAT): ₹577.9 million (+26.0% YoY)
  • Operating Cash Flow: ₹905 million (93.5% of Operating EBITDA)
  • Free Cash Flow (FCF): ₹-93 million (Q3 FY26)
  • Capital Expenditure (CapEx): ₹682 million (Q3 FY26)
  • Store Level Operating ROCE (older than 12 months): 77.7%

The Quality:
The company demonstrated margin improvement with Gross Margin expanding by 110 basis points YoY to 26.2%. Pharmacy Operating EBITDA margin saw a 10 bps uptick QoQ. Operating Cash Flow at 93.5% of Operating EBITDA is robust, indicating healthy cash generation from core operations. However, the Free Cash Flow for the quarter was negative at ₹-93 million, primarily due to substantial capital expenditure of ₹682 million, indicative of aggressive investment in store expansion.

The Grill:
Management highlights aggressive expansion as a key strategy, adding 182 net new stores to reach a total network of 5,112. A significant focus (116 net additions) is on locations beyond Tier-One cities, aiming for deeper market penetration. Growth drivers include cluster expansion, leveraging omni-channel capabilities, and increasing the share of private label products to enhance margins. While P&L metrics are strong, the negative FCF due to high CapEx is a key point for investors to monitor, assessing the efficiency of these expansion investments.

🚩 Risks & Outlook:

  • Specific Risks: Execution risks associated with rapid store rollouts, especially in new territories; intense competition in the retail pharmacy space; managing working capital efficiently during an expansion phase.
  • The Forward View: Investors will closely watch MedPlus's ability to sustain revenue and PAT growth, maintain margin expansion, and crucially, convert its strong operating cash flow into positive free cash flow as CapEx levels potentially normalize or scale further. The success of its private label strategy and omni-channel integration will be critical indicators for future profitability and market share.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.